BioXcel Therapeutics Income Statement (2017-2026) | BTAI

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)						0.14M	0.24M	0.21M	0.46M	0.34M	0.38M	0.58M	1.10M	0.21M	0.37M	0.17M	0.12M	0.10M	0.26M	0.21M
Gross Profit (Quarter)						0.13M	0.23M	0.20M	0.43M	-0.17M	-0.34M	0.50M	1.04M	-0.96M	-0.47M	0.15M	0.01M	0.09M	0.22M	-0.08M
Operating items
Amortization - Deferred Charges (Quarter)					0.32M	0.22M	0.32M	0.33M	0.36M	0.38M	0.31M	0.04M	0.10M	0.11M	0.22M	0.35M	0.39M	0.44M	0.47M	0.50M
Research & Development (Quarter)	13.51M	11.93M	12.53M	18.56M	17.91M	22.06M	32.46M	27.80M	26.97M	19.62M	9.93M	11.40M	8.03M	5.10M	5.90M	4.55M	10.26M	8.74M	6.70M	2.96M
Selling, General & Administrative (Quarter)	14.10M	14.88M	13.61M	12.92M	18.38M	17.05M	20.66M	23.59M	25.87M	24.34M	9.60M	13.26M	9.45M	7.68M	4.09M	5.70M	5.61M	5.38M	3.81M	7.19M
Restructuring Costs (Quarter)										4.16M			0.86M	1.55M	0.03M			0.19M
Other Operating Expenses (Quarter)						0.01M	0.01M	0.01M	0.03M	0.51M	0.71M	0.08M	0.06M	1.17M	0.83M	0.01M	0.11M	0.01M	0.03M	0.28M
Operating Expenses (Quarter)	27.61M	26.81M	26.13M	31.48M	36.29M	39.13M	53.13M	51.40M	52.87M	48.64M	20.25M	24.75M	18.40M	15.51M	10.86M	10.27M	15.97M	14.33M	10.54M	10.43M
Operating Income (Quarter)	-27.61M	-26.81M	-26.13M	-31.48M	-36.29M	-38.99M	-52.89M	-51.20M	-52.41M	-48.30M	-19.88M	-24.16M	-17.30M	-15.29M	-10.49M	-10.10M	-15.85M	-14.23M	-10.28M	-10.22M
EBIT (Quarter)	-27.61M	-26.81M	-26.13M	-31.48M	-36.29M	-38.99M	-52.89M	-51.20M	-52.41M	-48.30M	-19.88M	-24.16M	-17.30M	-15.29M	-10.49M	-10.10M	-15.85M	-14.23M	-10.28M	-10.22M
Non-operating items
Interest & Investment Income (Quarter)	0.01M	0.00M	0.05M	0.01M	0.20M	0.82M	1.49M	2.02M	1.62M	1.07M	0.95M	0.95M	0.67M	0.62M	0.37M	0.28M	0.23M	0.24M	0.32M	0.21M
Other Non Operating Income (Quarter)						0.06M	-0.48M	-0.25M	0.54M	-0.01M	0.11M	0.03M	12.03M	4.82M	3.30M	6.56M	0.66M	-12.55M	1.81M	1.52M
Non Operating Income (Quarter)						0.06M	-0.48M	-0.25M	0.54M	-0.01M	0.11M	0.03M	12.03M	4.82M	3.30M	6.56M	0.66M	-12.55M	1.81M	1.52M
Net income details
EBT (Quarter)	-27.62M	-26.82M	-26.09M	-31.47M	-37.35M	-41.65M	-54.87M	-52.22M	-53.70M	-50.10M	-22.06M	-26.82M	-20.23M	-18.47M	-13.94M	-13.81M	-19.45M	-18.36M	-14.36M	-13.71M
Profit After Tax (Quarter)	-27.62M	-26.81M	-26.12M	-31.47M	-37.67M	-41.80M	-54.81M	-52.80M	-53.52M	-50.49M	-22.26M	-26.79M	-8.30M	-13.65M	-10.86M	-7.25M	-19.19M	-30.91M	-12.54M	-12.69M
Income from Continuing Operations (Quarter)	-27.62M	-26.82M	-26.09M	-31.47M	-37.35M	-41.65M	-54.87M	-52.22M	-53.70M	-50.10M	-22.06M	-26.82M	-20.23M	-18.47M	-13.94M	-13.81M	-19.45M	-18.36M	-14.36M	-13.71M
Consolidated Net Income (Quarter)	-27.62M	-26.82M	-26.09M	-31.47M	-37.35M	-41.65M	-54.87M	-52.22M	-53.70M	-50.10M	-22.06M	-26.82M	-20.23M	-18.47M	-13.94M	-13.81M	-19.45M	-18.36M	-14.36M	-13.71M
Income towards Parent Company (Quarter)	-27.62M	-26.82M	-26.09M	-31.47M	-37.35M	-41.65M	-54.87M	-52.22M	-53.70M	-50.10M	-22.06M	-26.82M	-20.23M	-18.47M	-13.94M	-13.81M	-19.45M	-18.36M	-14.36M	-13.71M
Net Income towards Common Stockholders (Quarter)	-27.62M	-26.82M	-26.09M	-31.47M	-37.35M	-41.65M	-54.87M	-52.22M	-53.70M	-50.10M	-22.06M	-26.82M	-20.23M	-18.47M	-13.94M	-13.81M	-19.45M	-18.36M	-14.36M	-13.71M
Additional items
EPS (Basic) (Quarter)	-1.11	-0.96	-0.92	-1.12	-1.35	-1.49	-1.96	-1.84	-1.83	-1.72	-92.93	-13.89	-3.30	-5.15	-2.91	-1.50	-2.45	-2.18	0.65	-0.54
EPS (Weighted Average and Diluted) (Quarter)	-1.11	-0.96	-0.92	-1.12	-1.35	-1.49	-1.96	-1.84	-1.83	-1.72	-92.93	-13.89	-3.30	-5.15	-2.91	-1.50	-2.45	-2.18	0.65	-0.54
Shares Outstanding (Weighted Average) (Quarter)	24.74M	27.97M	26.37M	27.98M	27.98M	28.00M	28.02M	28.62M	29.19M	29.27M	1.82M	1.93M	2.22M	2.37M	2.54M	4.83M	7.84M	14.20M	12.21M	23.57M
Shares Outstanding (Diluted Average) (Quarter)	24.74M	27.97M	26.37M	0.03M	27.99M	28.00M	28.02M	28.62M	29.19M	29.03M	1.82M	1.93M	2.22M	2.65M	2.54M	4.83M	6.35M	14.20M	12.21M	23.57M
EBITDA (Quarter)	-27.61M	-26.81M	-26.13M	-31.48M	-36.29M	-38.99M	-52.89M	-51.20M	-52.41M	-48.30M	-19.88M	-24.16M	-17.30M	-15.29M	-10.49M	-10.10M	-15.85M	-14.23M	-10.28M	-10.22M
Interest Expenses (Quarter)	0.02M	0.01M	0.01M	0.01M	1.26M	3.48M	3.46M	3.03M	2.90M	2.88M	3.13M	3.61M	3.60M	3.79M	3.81M	3.99M	3.83M	4.37M	4.40M	3.70M
Shares Outstanding (Quarter)	27.97M	27.98M	27.98M	27.98M	28.02M	28.02M	1.76M	29.10M	29.27M	29.27M	1.87M	2.10M	2.52M	2.65M	3.10M	5.47M	6.62M	20.00M	22.33M	27.07M

Research Tools

Developers

BioXcel Therapeutics Income Statement (2017-2026) | BTAI

Research Tools

Developers

BioXcel Therapeutics Income Statement (2017-2026) | BTAI

Create an account

Sign In

Reset Password